CEO Comment June 2022 – Several Accomplishments & Positive Progress
It’s been a busy and eventful first half of 2022, so I just want to share some thoughts with you as we head into full summer. The fact is that a lot of positive things are happening in the company: · Actiste[®] is being used in Qatar with the aim to improve the lives of people living with diabetes. · Actiste[®] is being used for clinical research by diabetes patients in the United Kingdom. · We are getting closer to commercialization in the United Arab Emirates where a number of healthcare facilities have signed up for participation in the upcoming user pilot initiated